Lumakras is the next test of FDA’s hardening stance
After Exkivity signals another accelerated approval slowdown the Amgen drug tomorrow faces an adcom over its own conditional approval.
ESMO 2023 preview – Pluvicto splashes down among the late-breakers
Beyond lung cancer this year’s ESMO promises several other late-breaking datasets that could change clinical practice.
ESMO 2023 preview – J&J pulls a Mariposa rabbit out of the hat
And there won’t be a long to wait for the full data, with revelation that Mariposa features among numerous practice-changing late-breakers at ESMO.
Astra works to avoid a datopotamab double dip
As Tropion-Breast01 is toplined positive Astra ensures the markets know that overall survival isn’t a washout.
Bristol seeks novelty in TIGIT
Disclosure of BMS-986442’s second target antigen endorses Agenus, and is highly relevant for GSK and Compugen too.
Moderna moves on swiftly with its neoantigen immunotherapy
Lung cancer will soon join melanoma as a phase 3 indication for mRNA-4157, an asset Merck & Co last year endorsed to the tune of $250m.
